Wyeth Premarin Shortage Is Opportunity To Shift Patients To Cenestin – Barr
Executive Summary
Barr views current shortages of Wyeth-Ayerst's estrogen replacement therapy Premarin as an opportunity to encourage patient switches to its competing conjugated estrogen product Cenestin, Barr Senior VP-Sales & Marketing Timothy Catlett told analysts Dec. 6